Dendritic/tumor fusion cell-based vaccination against cancer

Archivum Immunologiae et Therapiae Experimentalis

Volumn 55, Issue 5, 2007, Pages 281-287

  Koido, Shigeo ^a,d   Hara, Eiichi ^b   Homma, Sadamu ^a   Fujise, Kiyotaka ^a   Gong, Jianlin ^c   Tajiri, Hisao ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SAITAMA CANCER CENTER   (Japan)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Jikei University School of Medicine ^*  (Japan)

Author keywords

Antigen specific CTL; Dendritic cells; Fusion cell vaccine; Tumor immunity

Indexed keywords

CANCER VACCINE;

B LYMPHOCYTE; CANCER IMMUNIZATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DENDRITIC CELL; HUMAN; IMMUNE RESPONSE; LUNG METASTASIS; NONHUMAN; REVIEW; T LYMPHOCYTE; TUMOR CELL; TUMOR IMMUNITY;

ANIMALS; CANCER VACCINES; CELL FUSION; DENDRITIC CELLS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; NEOPLASMS;

EID: 38349118249     PISSN: 0004069X     EISSN: 16614917     Source Type: Journal    
DOI: 10.1007/s00005-007-0034-6     Document Type: Review

References (58)

1. Akasaki Y., Kikuchi T., Homma S., Abe T., Kofe D. and Ohno T. (2001): Antitumor effect of immunizations with fusions of dendritic and glioma cells in a mouse brain tumor model. J. Immunother., 24, 106-113.
2. Avigan D., Vasir B., Gong J., Borges V., Wu Z., Uhl L., Atokins M., Mier J., McDermott D., Smith T., Giallambardo N., Stone C., Schadt K., Dolgoff J., Tetreault J. C., Villarroel M. and Kufe D. (2004): Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses. Clin. Cancer Res., 10, 4699-4708.
3. Banchereau J. and Steinman R. M. (1998): Dendritic cells and the control of immunity. Nature, 392, 245-252.
4. Barry M. and Bleackley R. C. (2002): Cytotoxic T lymphocytes: all roads lead to death. Nat. Rev. Immunol., 2, 401-409.
5. Cao X., Zhang W., Wang J., Zhang M., Huang X., Hamada H. and Chen W. (1999): Therapy of established tumour with a hybrid cellular vaccine generated by using granulocyte-macrophage colony-stimulating factor genetically modified dendritic cells. Immunology, 97, 616-625.
6. Cella M., Sallusto F. and Lanzavecchia A. (1997): Origin, maturation and antigen presenting function of dendritic cells. Curr. Opin. Immunol., 9, 10-16.
7. Chen D., Xia J., Tanaka Y., Chen H., Koido S., Wernet O., Mukherjee P., Gendler S. J., Kufe D. and Gong J. (2003): Immunotherapy of spontaneous mammary carcinoma with fusions of dendritic cells and mucin 1-positive carcinoma cells. Immunology, 109, 300-307.
8. Du Y. C., Lin P., Zhang J., Lu Y. R., Ning Q. Z. and Wang Q. (2006): Fusion of CpG-ODN-stimulating dendritic cells with Lewis lung cancer cells can enhance anti-tumor immune responses. Tissue Antigens, 67, 368-376.
9. Fabre J. W. (2001): The allogeneic response and tumor immunity. Nat. Med., 7, 649-652.
10. Forster R., Schubel A., Breitfeld D., Kremmer E., Renner-Muller I., Wolf E. and Lipp M. (1999): CCR7 coordinates the primary immune responses by establishing functional microenvironments in secondary lymphoid organs. Cell, 99, 23-33.
11. Gong J., Avigan D., Chen D., Wu Z., Koido S., Kashiwaba M. and Kufe D. (2000): Activation of antitumor cytotoxic T lymphocytes by fusions of human dendritic cells and breast carcinoma cells. Proc. Natl. Acad. Sci. USA, 97, 2715-2718.
12. Gong J., Chen D., Kashiwaba M. and Kufe D. (1997): Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat. Med., 3, 558-561.
13. Gong J., Chen D., Kashiwaba M., Li Y., Chen L., Takeuchi H., Qu H., Rowse G. J., Gendler S. J. and Kufe D. (1998): Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells. Proc. Natl. Acad. Sci. USA, 95, 6279-6283.
14. Gong J., Koido S., Chen D., Tanaka Y., Huang L., Avigan D., Anderson K., Ohno T. and Kufe D. (2002): Immunization against murine multiple myeloma with fusions of dendritic and plasmacytoma cells is potentiated by interleukin 12. Blood, 99, 2512-2517.
15. Gong J., Koido S., Kato Y., Tanaka Y., Chen D., Jonas A., Galinsky I., DeAngelo D., Avigan D., Kufe D. and Stone R. (2004): Induction of anti-leukemic cytotoxic T lymphocytes by fusion of patient-derived dendritic cells with autologous myeloblasts. Leuk. Res., 28, 1303-1312.
16. Gong J., Nikrui N., Chen D., Koido S., Wu Z., Tanaka Y., Cannistra S., Avigan D. and Kufe D. (2000): Fusions of human ovarian carcinoma cells with autologous or allogeneic dendritic cells induce antitumor immunity. J. Immunol., 165, 1705-1711.
17. Guo G., Chen S., Zhang J., Luo L., Yu J., Dong H., Xu H., Su Z. and Wu L. (2005): Antitumor activity of a fusion of esophageal carcinoma cells with dendritic cells derived from cord blood. Vaccine, 23, 5225-5230.
18. Heath W. R. and Carbone F. R. (2001): Cross-presentation in viral immunity and self-tolerance. Nat. Rev. Immunol., 1, 126-134.
19. Hiraoka K., Yamamoto S., Otsuru S., Nakai S., Tamai K., Morishita R., Ogihara T. and Kaneda Y. (2004): Enhanced tumor-specific long-term immunity of hemagglutinating virus of Japan-mediated dendritic cell-tumor fused cell vaccination by coadministration with CpG oligodeoxynucleotides. J. Immunol., 173, 4297-4307.
20. Holmes L. M., Li J., Sticca R. P., Wagner T. E. and Wei Y. (2001): A rapid, novel strategy to introduce tumor cell-specific cytotoxic T lymphocyte responses using instant dendritomas. J. Immunother., 24, 122-129.
21. Homma S., Kikuchi T., Ishiji N., Ochiai K., Takeyama H., Saotome H., Sagawa Y., Hara E., Kufe D., Ryan J. L., Ohno T. and Toda G. (2005): Cancer immunotherapy by fusion of dendritic and tumor cells and rh-IL-12. Eur. J. Clin. Invest., 35, 279-286.
22. Homma S., Sagawa Y., Ito T., Ohno T. and Toda G. (2006): Cancer immunotherapy using dendritic/tumor-fusion vaccine induces elevation of serum anti-nuclear antibody with better clinical responses. Clin. Exp. Immunol., 144, 41-47.
23. Homma S., Toda G., Gong J., Kufe D. and Ohno T. (2001): Preventive antitumor activity against hepatocellular carcinoma (HCC) induced by immunization with fusions of dendritic cells and HCC cells in mice. J. Gastroenterol., 36, 764-771.
24. Hosken N. A. and Bevan M. J. (1992): An endogenous antigenic peptide bypasses the class I antigen presentation defect in RMA-S. J. Exp. Med., 175, 719-729.
25. Iinuma H., Okinaga K., Fukushima R., Inaba T., Iwasaki K., Okinaga A., Takahashi I. and Kaneko M. (2006): Superior protective and therapeutic effects of IL-12 and IL-18 gene-transduced dendritic neuroblastoma fusion cells on liver metastasis of murine neuroblastoma. J. Immunol., 176, 3461-3469.
26. Iinuma T., Homma S., Noda T., Kufe D., Ohno T. and Toda G. (2004): Prevention of gastrointestinal tumors based on adenomatous polyposis coli gene mutation by dendritic cell vaccine. J. Clin. Invest., 113, 1307-1317.
27. Irie M., Homma S., Komita H., Zeniya M., Kufe D., Ohno T. and Toda G. (2004): Inhibition of spontaneous development of liver tumors by inoculation with dendritic cells loaded with hepatocellular carcinoma cells in C3H/HeNCRJ mice. Int. J. Cancer, 111, 238-245.
28. Kikuchi T., Akasaki Y., Abe T., Fukuda T., Saotome H., Ryan J. L., Kufe D. W. and Ohno T. (2004): Vaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12. J. Immunother., 27, 452-459.
29. Kikuchi T., Akasaki Y., Irie M., Homma S., Abe T. and Ohno T. (2001): Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells. Cancer Immunol. Immunother., 50, 337-344.
30. Klein J. and Sato A. (2000): The HLA system. First of two parts. N. Engl. J. Med., 343, 702-709.
31. Koido S., Hara E., Homma S., Torii A., Mitsunaga M., Yanagisawa M., Toyama Y., Kawahara H., Watanabe M., Yoshida S., Kobayashi S., Yanaga K., Fujise K. and Tajiri H. (2007): Streptococcal preparation OK-432 promotes fusion efficiency and enhances induction of antigen-specific CTL by fusions of dendritic cells and colorectal cancer cells. J. Immunol., 178, 613-622.
32. Koido S., Hara E., Homma S., Torii A., Toyama Y., Kawahara H., Watanabe M., Yanaga K., Fujise K., Tajiri H., Gong J. and Toda G. (2005): Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancer-specific antigens and induce antitumor immunity against autologous tumor cells. Clin. Cancer Res., 11, 7891-7900.
33. Koido S., Hara E., Torii A., Homma S., Toyama Y., Kawahara H., Ogawa M., Watanabe M., Yanaga K., Fujise K., Gong J. and Toda G. (2005): Induction of antigen-specific CD4 and CD8 mediated T cell responses by fusion of autologous dendritic cells and metastatic colorectal cancer cells. Int. J. Cancer, 117, 587-595.
34. Koido S., Kashiwaba M., Chen D., Gendler S., Kufe D. and Gong J. (2000): Induction of antitumor immunity by vaccination of dendritic cells transfected with MUC1 RNA. J. Immunol., 165, 5713-5719.
35. Koido S., Nikrui N., Ohana M., Xia J., Tanaka Y., Liu C., Durfee J., Lerner A. and Gong J. (2005): Assessment of fusion cells from patient-derived ovarian carcinoma cells and dendritic cells as a vaccine for clinical use. Gynecol. Oncol., 99, 462-471.
36. Koido S., Ohana M., Liu C., Nikrui N., Durfee J., Lerner A. and Gong J. (2004): Dendritic cells fused with human cancer cells: morphology, antigen expression and T cell stimulation. Clin. Immunol., 113, 261-269.
37. Koido S., Tanaka Y., Chen D., Kufe D. and Gong J. (2002): The kinetics of in vivo priming of CD4 and CD8 T cells by dendritic/tumor fusion cells in MUC1-transgenic mice. J. Immunol., 168, 2111-2117.
38. Koido S., Tanaka Y., Tajiri H. and Gong J. (2007): Generation and functional assessment of antigen-specific T cells stimulated by fusion of dendritic cells and allogeneic breast cancer cells. Vaccine, 25, 2610-2619.
39. Kufe D. W. (2000): Smallpox, polio and now a cancer vaccine? Nat. Med., 6, 252-253.
40. Liu Y., Zhang W., Chan T., Saxena A. and Xiang J. (2002): Engineered fusion hybrid vaccine of IL-4 gene-modified myeloma and relative mature dendritic cells enhances antitumor immunity. Leuk. Res., 26, 757-763.
41. Mackensen A., Herbst B., Chen J. L., Kohler G., Noppen C., Herr W., Spagnoli G., Cerundolo V. and Lindemann A. (2000): Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells. Int. J. Cancer, 86, 385-392.
42. Marzo A. L., Kinnear B. F., Lake R. A., Frelinger J. J., Collins E. J., Robinson B. W. and Scott B. (2000): Tumor-specific CD4+ T cells have a major "post-licensing" role in CTL mediated anti-tumor immunity. J. Immunol., 165, 6047-6055.
43. Nestle F. O., Alijagic S., Gilliet M., Sun Y., Grabbe S., Dummer R., Burg G. and Schadendorf D. (1998): Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med., 4, 328-332.
44. Paglia P., Chiodoni C., Rodolfo M. and Colombo M. P. (1996): Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J. Exp. Med., 183, 317-322.
45. Patton S., Gendler S. J. and Spicer A. P. (1995): The epithelial mucin, MUC1, of milk, mammary gland and other tissues. Biochim. Biophys. Acta, 1241, 407-423.
46. Rowse G. J., Tempero R. M., VanLith M. L., Hollingsworth M. A. and Gendler S. J. (1998): Tolerance and immunity to MUC1 in a human MUC1 transgenic murine model. Cancer Res., 58, 315-321.
47. Russo V., Tanzarella S., Dalerba P., Rigatti D., Rovere P., Villa A., Bordignon C. and Traversari C. (2000): Dendritic cells acquire the MAGE-3 human tumor antigen from apoptotic cells and induce a class I-restricted T cell response. Proc. Natl. Acad. Sci. USA, 97, 2185-2190.
48. Savai R., Schermuly R. T., Schneider M., Pullamsetti S. S., Grimminger F., Seeger W. and Banat G. A. (2006): Hybrid-primed lymphocytes and hybrid vaccination prevent tumor growth of Lewis lung carcinoma in mice. J. Immunother., 29, 175-187.
49. Sigal L. J., Crotty S., Andino R. and Rock K. L. (1999): Cytotoxic T-cell immunity to virus-infected non-haematopoietic cells requires presentation of exogenous antigen. Nature, 398, 77-80.
50. Steinman R. M. (1991): The dendritic cell system and its role in immunogenicity. Annu. Rev. Immunol., 9, 271-296.
51. Steinman R. M. and Cohn Z. A. (1973): Identification of a novel cell type in tissue distribution. J. Exp. Med., 137, 1142-1162.
52. Steinman R. M., Hawiger D. and Nussenzweig M. C. (2003): Tolerogenic dendritic cells. Annu. Rev. Immunol., 21, 685-711.
53. Tanaka Y., Koido S., Chen D., Gendler S. J., Kufe D. and Gong J. (2001): Vaccination with allogeneic dendritic cells fused to carcinoma cells induces antitumor immunity in MUC1 transgenic mice. Clin. Immunol., 101, 192-200.
54. Tanaka Y., Koido S., Ohana M., Liu C. and Gong J. (2005): Induction of impaired antitumor immunity by fusion of MHC class II-deficient dendritic cells with tumor cells. J. Immunol., 174, 1274-1280.
55. Tanaka Y., Koido S., Xia J., Ohana M., Liu C., Cote G. M., Sawyer D. B., Calderwood S. and Gong J. (2004): Development of antigen-specific CD8+ CTL in MHC class I-deficient mice through CD4 to CD8 conversion. J. Immunol., 172, 7848-7858.
56. Thurner B., Haendle I., Roder C., Dieckmann D., Keikavoussi P., Jonuleit H., Bender A., Maczek C., Schreiner D., von den Driesch P., Brocker E. B., Steinman R. M., Enk A., Kampgen E. and Schuler G. (1999): Vaccination with Mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J. Exp. Med., 190, 1669-1678.
57. Wang J., Saffold S., Cao X. T., Krauss J. and Chen W. (1998): Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines. J. Immunol., 161, 5516-5524.
58. Xia J., Tanaka Y., Koido S., Liu C., Mukherjee P., Gendler S. J. and Gong J. (2003): Prevention of spontaneous breast carcinoma by prophylactic vaccination with dendritic//tumor fusion cells. J. Immunol., 170, 1980-1986.